Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by California Public Employees Retirement System

California Public Employees Retirement System raised its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 15.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 131,344 shares of the biopharmaceutical company's stock after buying an additional 17,225 shares during the period. California Public Employees Retirement System owned approximately 0.14% of Ultragenyx Pharmaceutical worth $5,526,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of RARE. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Ultragenyx Pharmaceutical by 0.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 177,756 shares of the biopharmaceutical company's stock worth $9,874,000 after purchasing an additional 947 shares in the last quarter. Captrust Financial Advisors increased its holdings in shares of Ultragenyx Pharmaceutical by 129.3% in the 3rd quarter. Captrust Financial Advisors now owns 11,428 shares of the biopharmaceutical company's stock valued at $635,000 after purchasing an additional 6,445 shares in the last quarter. Benjamin Edwards Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $338,000. XTX Topco Ltd boosted its position in Ultragenyx Pharmaceutical by 95.2% during the third quarter. XTX Topco Ltd now owns 14,629 shares of the biopharmaceutical company's stock worth $813,000 after purchasing an additional 7,134 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd grew its stake in Ultragenyx Pharmaceutical by 193.1% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 19,151 shares of the biopharmaceutical company's stock valued at $1,064,000 after acquiring an additional 12,617 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Piper Sandler reduced their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. Wedbush restated a "neutral" rating and set a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Wells Fargo & Company lifted their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research report on Friday, December 20th. Finally, Canaccord Genuity Group lifted their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average price target of $92.79.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE traded up $0.98 on Friday, reaching $34.14. 1,103,595 shares of the company's stock were exchanged, compared to its average volume of 811,190. The stock has a fifty day simple moving average of $39.38 and a 200-day simple moving average of $44.88. The firm has a market cap of $3.21 billion, a price-to-earnings ratio of -5.38 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a 52 week low of $29.59 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The business had revenue of $164.88 million for the quarter, compared to analysts' expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. As a group, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Buying and Selling

In related news, CAO Theodore Alan Huizenga sold 967 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $40,710.70. Following the sale, the chief accounting officer now owns 50,265 shares of the company's stock, valued at approximately $2,116,156.50. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John Richard Pinion sold 14,439 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $607,881.90. Following the completion of the sale, the insider now owns 107,766 shares in the company, valued at approximately $4,536,948.60. This represents a 11.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 124,643 shares of company stock worth $5,256,268 in the last three months. Insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.